ABSTRACT
Our recent data demonstrates a critical role of the RIG-I-like receptor (RLR) family in regulating antifungal immunity against Aspergillus fumigatus in a murine model. However, the importance of this pathway in humans and the cell type(s) which utilize this innate immune receptor to detect A. fumigatus remains unresolved. Here using patients who underwent hematopoietic stem cell transplantation (HSCT), we demonstrate that a polymorphism in human MAVS present in the donor genome was associated with the incidence of invasive pulmonary aspergillosis (IPA). Moreover, in a separate cohort of confirmed IPA patients, polymorphisms in the IFIH1 gene alter the inflammatory response, including interferon-responsive chemokines. Returning to our murine model, we now demonstrate that CD11c+ SiglecF+ alveolar macrophages require Mavs expression to maintain host resistance against A. fumigatus. Our data support the role of MAVS signaling in mediating antifungal immunity in both mice and human at least in part through the role of MAVS-dependent signaling in alveolar macrophages.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research in this study was supported in part by institutional startup funds to JJO in part through the Dartmouth Lung Biology Center for Molecular, Cellular, and Translational Research grant P30 GM106394 (PI: Bruce A. Stanton) and Center for Molecular, Cellular and Translational Immunological Research grant P30 GM103415 (PI: William R. Green). JJO was partially supported by a Munck-Pfefferkorn Award from Dartmouth College and NIH R01 AI139133 grant. SMB is supported by the Division of Intramural Research, National Institutes of Health, National Institute of Allergy and Infectious Diseases. AC and CC were supported by the Fundacao para a Ciencia e Tecnologia (FCT) (PTDC/SAU-SER/29635/2017, PTDC/MED-GEN/28778/2017, UIDB/50026/2020, UIDP/50026/2020, and CEECIND/04058/2018), the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) (NORTE-01-0145-FEDER-000039), the European Union's Horizon 2020 research and innovation programme under grant agreement no. 847507, and the "la Caixa" Foundation (ID 100010434) and FCT under the agreement LCF/PR/HR17/52190003. The funders had no role in the preparation or publication of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study approvals. All animal experiments were approved by the Dartmouth College Institutional Animal Care and Use Committee under protocol number 00002168. For our human studies approval was obtained from the following institutional review boards: Ethics Committee for Research in Life and Health Sciences of the University of Minho (SECVS-125/2014), Ethics Committee of the Lisbon Academic Medical Centre (HSM-632/14), Health Ethics Committee of the Portuguese Institute of Oncology - Porto (CES.26/015), and from the National Data Protection Commission (CNPD, 1950/2015). All research was in compliance with all local relevant ethical regulations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interests: The authors have declared that no conflict of interest exists.
Supplemental Figure 3 was added; Additional discussion of other potential non-hematopoietic sources of IFN was added
Data Availability
All data will be available upon request
Abbrevations
- IPA
- invasive pulmonary aspergillosis
- HCST
- hematopoietic stem cell transplantation
- GMM
- glucose minimal media
- PBS
- phosphate buffered saline
- i.t.
- intratracheal
- BALF
- bronchoalveolar lavage fluid
- GMS
- Grocott-Gomori methenamine silver
- SNP
- single nucleotide polymorphism
